Kangyuan

Jiangsu Kanion Pharmaceutical is a leading Chinese pharmaceutical company dedicated to the modernization of Traditional Chinese Medicine (TCM) and the development of innovative chemical and biological drugs. The company is renowned for its robust R&D capabilities and high-quality manufacturing standards, focusing on therapeutic areas such as gynecology, pediatrics, orthopedics, and cardiovascular diseases. Flagship products like Re-Du-Ning Injection and Gui-Zhi-Fu-Ling Capsules have established Kanion as a dominant player in the Chinese TCM market. In recent years, the company has strategically expanded into the biologics sector, advancing a pipeline of monoclonal antibodies targeting oncology indications. Publicly listed on the Shanghai Stock Exchange, Kanion continues to integrate traditional wisdom with modern science to provide effective healthcare solutions.